GET THE APP

Lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) and soluble LOX-1 (sLOX-1): implications in atherosclerosis-related diseases

Endocrinology & Diabetes Research.ISSN: 2470-7570

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) and soluble LOX-1 (sLOX-1): implications in atherosclerosis-related diseases

The development of atherosclerosis is a multifactorial process, but oxidized low-density lipoprotein (oxLDL) has been recognized as a critical player in the pathogenesis of the disease. The lectin-like oxLDL receptor-1 (LOX-1) has recently been identified as the primary scavenger receptor of oxLDL, which mediates their detrimental biological effects in endothelial cells. Subsequent studies have revealed that LOX-1 is also expressed by other cells highly implicated in atherosclerosis, such as monocytes/macrophages, vascular smooth muscle cells, cardiomyocytes and platelets. On one hand interaction of oxLDL with LOX-1 promotes oxidative stress and transcription of pro-inflammatory molecules, and on the other hand increases the expression of LOX-1 as a result of the vicious cycle, activated by the atherogens. Thus, LOX-1 has been suggested as a key molecule in vascular inflammation and in atherosclerotic plaque formation, destabilization, erosion and rupture.

Special Features

Full Text

View

Track Your Manuscript

Media Partners

Associations